Nektar Therapeutics (NASDAQ: NKTR) is a Healthcare company (Biotechnology) with a market capitalization of $1.0B. The Maz Rating grades it against the other companies in its sector.
Nektar Therapeutics's current Maz Rating and its five factor grades are for members: log in to see them.
At $35.91, Nektar Therapeutics trades at 19.9x sales and 1.5x book value. Over the last twelve months it generated about $52M of revenue and a net loss of $184M. It runs a gross margin of 99.7%, an operating margin of -301.8% and a net margin of -339.7%. It shows return on equity of -29.3%, return on invested capital of -16.0% and a free cash flow yield of -25.0%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 9.00. Over the past 52 weeks the share price ranged from $33.40 to $109.00, with a beta of 1.15.
Nektar Therapeutics does not currently pay a dividend.
33 Wall Street analyst ratings cover the stock: 22 Buy, 6 Hold and 5 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Nektar Therapeutics (NKTR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 53.8% / 30% · Interest income / Revenue 102.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 34.7% / 33% · Receivables / Mkt Cap (36m) 0.35% / 49% · Interest income / Revenue 102.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 34.7% / 33.33% · Receivables / Mkt Cap (24m) 0.35% / 33.33% · Interest income / Revenue 102.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 7.76% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 66.5% / 33.33% · Receivables / Avg Assets (4Q) 0.51% / 33.33% · Interest income / Revenue 102.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 59.2% / 33.33% · (Cash+Recv) / Total Assets 59.8% / 33.33% · Interest income / Revenue 102.0% / 5% | Fail |
No. As of September 2026, Nektar Therapeutics (NKTR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Nektar Therapeutics is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 102.0% of each dividend: Nektar Therapeutics's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.